Omnicell (OMCL) Moves to Strong Buy: Rationale Behind the Upgrade
Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for October 4th
OMCL and SFBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 4, 2024.
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
Earnings Estimates Moving Higher for Omnicell (OMCL): Time to Buy?
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Omnicell (OMCL) Introduces Central Med Automation Service
Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.
Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript
Omnicell, Inc. (NASDAQ:OMCL ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President Randall Lipps - Founder, Chairman, President and CEO Nchacha Etta - Executive Vice President and CFO Conference Call Participants Stan Berenshteyn - Wells Fargo Scott Schoenhaus - KeyBanc Matt Hewitt - Craig-Hallum Capital Group David Larsen - BTIG Bill Sutherland - The Benchmark Company Anna Kruszenski - Barclays Allen Lutz - Bank of America Jessica Tassan - Piper Sandler Anne Samuel - JPMorgan Operator Good morning and thank you for standing by. My name is Aaron, and I will be your conference operator for today.
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.57 per share a year ago.
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) Banks on Product Launches, Global Growth
Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
